Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status
Updated: January 23, 2015

Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Zolpidem ODT	Sublinox	zolpidem tartrate	10mg	sublingual orally disintegrating tablet	02434946
Apotex Inc.	Apo-Zolpidem ODT	Sublinox	zolpidem tartrate	5mg	sublingual orally disintegrating tablet	02436159
Auro Pharma Inc.	Auro-Finasteride 1mg	Propecia	finasteride	1mg	FC tablet	02428148
Omega Laboratories Ltd.	Glycopyrrolate Injection	Glycopyrrolate	glycopyrrolate	0.2mg/ mL	IM, IV solution	02382857
Pharmascience Inc.	Pms-Zoledronic Acid	Zometa Concentrate	zoledronic acid monohydrate	4mg/5mL	IV solution	02403056

Ontario

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Ranbaxy Pharmaceuticals	Ran-Ramipril	Altace	ramipril	15mg	capsule	02425548
Sandoz Canada Inc.	Sandoz Memantine FCT	Ebixa	memantine HCl	10mg	FC tablet	02375532
Teva Canada Limited	Teva-Erlotinib	Tarceva	erlotinib HCl	25mg	FC tablet	02377691
Teva Canada Limited	Teva-Erlotinib	Tarceva	erlotinib HCl	100mg	FC tablet	02377705
Teva Canada Limited	Teva-Erlotinib	Tarceva	erlotinib HCl	150mg	FC tablet	02377713